Back to top
more

Amgen (AMGN)

(Delayed Data from NSDQ)

$319.66 USD

319.66
1,467,828

+2.18 (0.69%)

Updated Oct 4, 2024 04:00 PM ET

After-Market: $319.25 -0.41 (-0.13%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value C Growth B Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 33% (83 out of 252)

Industry: Medical - Biomedical and Genetics

Better trading starts here.

Zacks News

Amgen (AMGN) Outpaces Stock Market Gains: What You Should Know

In the latest trading session, Amgen (AMGN) closed at $206.78, marking a +1.8% move from the previous day.

Esperion (ESPR) to Cut 40% Workforce, Revamp Cost Structure

Esperion (ESPR) is set reduce its workforce by 40% and start targeted program savings to reduce its operational expense and deliver consistent growth.

Zacks Value Trader Highlights: AT&T, Verizon, Amgen, Poshmark, and The RealReal

Zacks Value Trader Highlights: AT&T, Verizon, Amgen, Poshmark, and The RealReal

Tracey Ryniec headshot

How to Find Stocks on Sale in 2021

Looking for hidden gems isn't too hard with this simple stock screen.

Indrajit Bandyopadhyay headshot

3 Small Biotech Stocks in Focus on World Arthritis Day

Here we discuss three drugs or biotech companies with promising candidates in their pipeline for Arthritis indications.

AstraZeneca (AZN) COVID-19 Antibody Meets Goal in TACKLE Study

AstraZeneca (AZN) posts positive results from the phase III TACKLE study on the AZD7442 combo for treating mild-to-moderate COVID-19 in the outpatient setting. The study has met its primary endpoint.

Amgen (AMGN) Reports New Data From Lumakras Combo Study

Amgen (AMGN) reports new combination data from the phase Ib CodeBreaK 101 study. It also buys a stake in Neumora Therapeutics to advance novel therapies for brain diseases.

Bristol Myers (BMY) UC Candidate Fails in Phase II Study

Bristol Myers (BMY) suffers a setback as its phase II study of deucravacitinib for the treatment of moderate to severe ulcerative colitis fails to meet primary and secondary endpoints.

Biohaven (BHVN) Q3 Nurtec Preliminary Sales Top Expectations

Biohaven's (BHVN) sole marketable drug, Nurtec ODT reports preliminary sales for the third quarter, which beat expectations.

This 1 Medical Stock Could Beat Earnings: Why It Should Be on Your Radar

Finding stocks expected to beat quarterly earnings estimates becomes an easier task with our Zacks Earnings ESP.

Biotech Stock Roundup: XLRN Up on Takeover Rumor, NVAX, BIIB Offer Updates & More

Regulatory and pipeline updates from bigwigs like Biogen (BIIB) and Novavax (NVAX) have been some of the key highlights in the biotech sector during the past week.

AbbVie's (ABBV) Migraine Prevention Drug Qulipta Gets FDA Nod

The FDA approves AbbVie's (ABBV) Qulipta (atogepant) for preventive treatment of episodic migraine in adults.

The Zacks Analyst Blog Highlights: Tesla, JPMorgan, Oracle, Amgen and Lam Research

The Zacks Analyst Blog Highlights: Tesla, JPMorgan, Oracle, Amgen and Lam Research

Sheraz Mian headshot

Top Analyst Reports for Tesla, JPMorgan & Oracle

Today's Research Daily features new research reports on 16 major stocks, including Tesla, Inc. (TSLA), JPMorgan Chase & Co. (JPM), and Oracle Corporation (ORCL).

Biohaven (BHVN) Phase III Multiple System Atrophy Study Fails

Biohaven's (BHVN) myeloperoxidase enzyme inhibitor, verdiperstat fails to statistically differentiate from placebo in improving disease progression in patients with multiple system atrophy in a late-stage study.

Amgen (AMGN) Repatha Gets FDA Nod for Expanded Use in Kids

FDA approves Amgen's (AMGN) Repatha for pediatric patients, 10 years of age and older, with familial hypercholesterolemia, both heterozygous and homozygous forms.

Onconova (ONTX) KRAS Inhibitor Shows Activity in Lung Cancer

Onconova (ONTX) is developing a combination of its rigosertib plus Bristol-Myers' Opdivo for treating cancer with solid tumors. Preliminary data from the phase I/II study demonstrates disease control potential.

Mirati (MRTX) Reports Positive Data From Colorectal Cancer Study

Mirati (MRTX) reports positive data from a cohort of the phase I/IIstudy evaluating its KRAS inhibitor adagrasib in patients with KRAS G12C-mutated colorectal cancer.

The Zacks Analyst Blog Highlights: Bank of America, PepsiCo, Wells Fargo, T-Mobile and Amgen

The Zacks Analyst Blog Highlights: Bank of America, PepsiCo, Wells Fargo, T-Mobile and Amgen

Sheraz Mian headshot

Top Analyst Reports for Bank of America, PepsiCo & Wells Fargo

Today's Research Daily features new research reports on 16 major stocks, including Bank of America Corporation (BAC), PepsiCo, Inc. (PEP), and Wells Fargo & Company (WFC).

Stock Market News for Sep 10, 2021

U.S. stock markets closed lower on Thursday as investors await the decision of the U.S. Federal Reserve with regard to the monetary policy.

Merck's (MRK) Keytruda Gets Nod for Expanded Use in China

Merck's (MRK) Keytruda gets approval in combination with chemotherapy in the first-line setting for advanced esophageal and GEJ cancer in China based on data from the phase III KEYNOTE-590 study.

Impel (IMPL) Gets FDA Nod for Trudhesa in Migraine Treatment

The FDA approves Impel's (IMPL) Trudhesa nasal spray for the acute treatment of migraine with or without aura in adults.

Amgen (AMGN) Outpaces Stock Market Gains: What You Should Know

Amgen (AMGN) closed at $225.96 in the latest trading session, marking a +1.17% move from the prior day.

Amgen (AMGN) Down 2.2% Since Last Earnings Report: Can It Rebound?

Amgen (AMGN) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.